Riskpilot← Back to searchSign inGet full accessGSK UTVIKLING AS
ASActiveOrg 925732346Rørgata 8, 6517 Kristiansund NBuying and selling of own real estate · NACE 6811Est. 20200 employees
Revenue 2024
NOK 95K
-99% vs 2023
EBITDA margin
-150.5%
-127% vs 2023
Equity ratio
2.0%
Financial strength
Net profit 2024
NOK -155K
-139% vs 2023
| Revenue | NOK 95K | -99% |
| EBITDA | NOK -143K | -127% |
| Net profit | NOK -155K | -139% |
| Total assets | NOK 13M | +25% |
| Equity | NOK 257K | -38% |
| Employees | 0 | — |
Legal name
GSK UTVIKLING AS
Org number
925732346
Legal form
Aksjeselskap
NACE code
6811 · Buying and selling of own real estate
Founded
2. oktober 2020
Share capital
NOK 100 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap.
Company purpose
Eiendom og andre produkter/tjenester som naturlig hører sammen med dette, herunder å delta i andre selskap med lignende virksomhet, og kjøp og salg av aksjer, boliger, bygging av boliger eller på annen måte gjøre seg interessert i andre foretak.
Address
Rørgata 8, 6517 Kristiansund N
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 9 650 | 95 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 |
| EBITDA | −9 | −11 | −76 | 538 | −143 |
| Depreciation & amort. | −0 | −0 | −7 | −32 | −33 |
| EBIT | −9 | −11 | −82 | 506 | −176 |
| Net financials | 0 | 0 | −2 | −1 | 0 |
| Profit before tax | −9 | −11 | −85 | 504 | −175 |
| Tax | −0 | −0 | −23 | 111 | −20 |
| Net profit | −9 | −11 | −62 | 393 | −155 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 94 | 80 | 6 794 | 10 366 | 12 991 |
| Equity | 91 | 80 | 19 | 412 | 257 |
| Long-term debt | 0 | 0 | 3 620 | 2 640 | 1 781 |
| Short-term debt | 3 | 0 | 3 155 | 7 314 | 10 953 |
| Total debt | 3 | 0 | 6 775 | 9 954 | 12 734 |
EBITDA margin
-150.5%
This company
15.8%
Market median
-1053% vs market
20202024
Equity ratio
2.0%
This company
38.2%
Market median
-95% vs market
20202024
Return on equity
-60.3%
This company
18.4%
Market median
-428% vs market
20202024
Net profit margin
-163.2%
This company
8.1%
Market median
-2115% vs market
20202024
Asset turnover
0.01×
This company
1.12×
Market median
-99% vs market
20202024
Debt / equity
49.55×
This company
0.62×
Market median
-7892% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-08-26 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
HO Chief Executive Officer | Chief Executive Officer | 2020 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (5) | ||
| Board of Directors | 2022 | |
| Chairman | 2025 | |
| Board of Directors | 2025 | |
| Chairman | 2022 | |
| Board of Directors | 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 25% | 25% | 2024 | |
| Company | 25% | 25% | 2024 | |
| Company | 25% | 25% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Knut Ellingvåg Og Sønner As
GSK UTVIKLING AS Board members of GSK UTVIKLING AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Hans Olav Søbstad | Chief Executive Officer | 0 companies |
| Pål Erik Forsnes | Board of Directors | 0 companies |
| Joar Eide | Chairman | 0 companies |
| Per Arne Fladseth | Board of Directors | 0 companies |
| Øyvind Gjøen | Chairman | 0 companies |
| Per Gunnar Vidhammer | Board of Directors | 0 companies |